The chemical class termed Vmn1r34 Inhibitors encompasses a theoretical assortment of compounds chosen for their potential to indirectly modulate the signaling pathways or cellular processes associated with the activity of Vmn1r34. These compounds, while not directly inhibiting Vmn1r34, are considered due to their potential to influence the receptor's function by targeting key signaling components or pathways integral to GPCR function. This approach highlights the complexity of cellular signaling and the interconnected nature of the pathways that regulate pheromone detection and response.
By targeting various signaling components such as GPCRs, ion channels, or enzymes involved in the synthesis or degradation of signaling molecules, these chemicals offer a broad theoretical framework for exploring the potential indirect modulation of Vmn1r34 activity. This strategy emphasizes the intricate web of cellular signaling mechanisms and the potential for various chemical inhibitors to influence receptor activity through changes in the signaling environment. For example, modulating adrenergic or serotoninergic signaling landscapes with antagonists like propranolol or ondansetron, respectively, could indirectly impact Vmn1r34 functionality by altering the overall signaling context. Similarly, the use of ion channel blockers or signal transduction pathway modulators offers a multifaceted approach to potentially affecting Vmn1r34's activity. This theoretical exploration into the indirect modulation of Vmn1r34 through chemical intervention illustrates the complex interplay between different signaling systems and the potential for such interventions to influence the functionality of specific receptors within the extensive network of cellular signaling pathways, underscoring the importance of understanding the broader biological context in which proteins operate and the complex interplay between different cellular processes and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist that can modulate GPCR signaling, potentially affecting Vmn1r34 indirectly. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, may alter GPCR-mediated processes, potentially impacting Vmn1r34. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, might affect GPCR signaling pathways, influencing Vmn1r34 indirectly. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect noradrenergic signaling, possibly related to Vmn1r34. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist, might modulate GPCR pathways, potentially influencing Vmn1r34 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, could affect calcium signaling pathways, potentially related to Vmn1r34. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, could affect GPCR-mediated signaling pathways involved with Vmn1r34. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r34. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r34 function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, might influence GPCR-mediated signaling pathways related to Vmn1r34. | ||||||